Dec 29
Current report
8-K
Events of Dec 19
Bankruptcy or receivership, Other events
CLSDQ · Clearside Biomedical, Inc. · Documents
Going-concern doubt
— flagged Nov 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about our ability to continue as a going concern within one year after the date the financial statements are issued. Based on our current plans and forecasted expenses and our cash and cash equivalents, we do not believe we will be able to fund our operations for the next 12 months from the date of this filing.”View the 10-Q filed Nov 14, 2025
Market Cap
$1.30M
Shares
5.23M
Volume
—
Avg daily vol (3M)
—
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2025
Dec 8
Current report
8-K
Delisting notice or listing transfer
Nov 25
Current report
8-K
Events of Nov 23
Bankruptcy or receivership, Delisting notice or listing transfer, Regulation FD disclosure
Nov 14
Quarterly report
10-Q
FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Revenue $201K
▼ 80.6%
Net loss $5.97M
Diluted EPS -$1.14
Oct 7
Current report
8-K
Other events
Sep 11
Current report
8-K
Events of Sep 10
Charter or bylaw amendment, or fiscal year change
Sep 11
Current report
8-K
Events of Sep 10
Charter or bylaw amendment, or fiscal year change
Sep 8
Current report
8-K
Events of Sep 4
Entered into a material agreement
Sep 3
Current report
8-K
Events of Aug 28
Delisting notice or listing transfer, Shareholder vote results
Aug 14
Aug 8
Quarterly report
10-Q
FY2025 Q2, ended Jun 30
Quarterly report for FY2025 Q2
Revenue $492K
▲ 446.7%
Net loss $4.5M
Diluted EPS -$0.06
Aug 4
Proxy statement
DEF 14A
Meeting Aug 29, 2025
Proxy statement
Jul 25
Proxy statement
PRE 14A
Meeting Aug 29, 2025
Proxy statement
Jul 17
May 30
Current report
8-K
Charter or bylaw amendment, or fiscal year change, Shareholder vote results
May 15
Quarterly report
10-Q
FY2025 Q1, ended Mar 31
Quarterly report for FY2025 Q1
Revenue $2.33M
▲ 913.0%
Net loss $8.22M
Diluted EPS -$0.11
May 14
Current report
8-K
Financial results
Apr 18
Proxy statement
DEF 14A
Meeting May 30, 2025
Proxy statement
Apr 18
Annual report to holders
ARS
Annual report to holders
Apr 18
Proxy statement
DEFA14A
Proxy statement
Apr 8
Proxy statement
PRE 14A
Meeting May 30, 2025
Proxy statement
Mar 27
Current report
8-K
Financial results, Regulation FD disclosure
Mar 27
Annual report
10-K
FY2024, ended Dec 31
Annual report for FY2024
Revenue $1.66M
▼ 79.8%
Net loss $34.35M
Diluted EPS -$0.47
Feb 13
Current report
8-K
Events of Feb 7
Delisting notice or listing transfer
2024
Dec 12
Current report
8-K
Regulation FD disclosure, Other events
Nov 12
Current report
8-K
Financial results
Nov 12
Quarterly report
10-Q
FY2024 Q3, ended Sep 30
Quarterly report for FY2024 Q3
Revenue $1.04M
▲ 20.8%
Net loss $7.69M
Diluted EPS -$0.10
Oct 9
Current report
8-K
Regulation FD disclosure, Other events
Aug 12
Current report
8-K
Financial results
Aug 12
Quarterly report
10-Q
FY2024 Q2, ended Jun 30
Quarterly report for FY2024 Q2
Revenue $90K
▼ 91.2%
Net loss $7.59M
Diluted EPS -$0.10
Jul 24
Current report
8-K
Regulation FD disclosure
Jun 20
Current report
8-K
Shareholder vote results
May 10
Quarterly report
10-Q
FY2024 Q1, ended Mar 31
Quarterly report for FY2024 Q1
Revenue $230K
▲ 5650.0%
Net loss $11.76M
Diluted EPS -$0.17
May 9
Current report
8-K
Financial results
Apr 26
Proxy statement
DEF 14A
Meeting Jun 20, 2024
Proxy statement
Apr 26
Annual report to holders
ARS
Annual report to holders
Apr 26
Proxy statement
DEFA14A
Proxy statement
Apr 16
Current report
8-K
Events of Apr 15
Director or officer change, or executive pay, Regulation FD disclosure
Mar 12
Current report
8-K
Financial results
Mar 12
Annual report
10-K
FY2023, ended Dec 31
Annual report for FY2023
Revenue $8.23M
▲ 519.9%
Net loss $32.49M
Diluted EPS -$0.53
Feb 8
Current report
8-K
Events of Feb 6
Entered into a material agreement, Regulation FD disclosure
Feb 1
Current report
8-K
Events of Jan 31
Entered into a material agreement
2023
Dec 28
Current report
8-K
Events of Dec 22
Entered into a material agreement
Nov 13
Current report
8-K
Financial results
Nov 13
Quarterly report
10-Q
FY2023 Q3, ended Sep 30
Quarterly report for FY2023 Q3
Revenue $859K
▲ 222.9%
Net loss $9.27M
Diluted EPS -$0.15
Nov 3
Current report
8-K
Events of Nov 1
Entered into a material agreement
Sep 29
Current report
8-K
Events of Sep 27
Delisting notice or listing transfer
Aug 14
Current report
8-K
Financial results
Aug 14
Quarterly report
10-Q
FY2023 Q2, ended Jun 30
Quarterly report for FY2023 Q2
Revenue $1.02M
▲ 165.1%
Net loss $9.11M
Diluted EPS -$0.15
Jun 22
Current report
8-K
Shareholder vote results
Showing 1–50 of 114 documents